{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.8","value":"214"},{"groupId":"OG001","spread":"175","value":"304"},{"groupId":"OG002","spread":"241","value":"619"},{"groupId":"OG003","spread":"3130","value":"981"},{"comment":"Two participants had values above the upper limit of quantification, meaning data for PK parameters could not be determined.","groupId":"OG004","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Ctrough was defined as the lowest concentration of zilurgisertib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"MEAN","populationDescription":"PK Evaluable Population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Day 15 of Cycle 1: pre-dose; 2, 4, and 6-8 hours post-dose","title":"Ctrough of Zilurgisertib","type":"SECONDARY","unitOfMeasure":"nanomolar"}